Harrow, Inc.NASDAQ: HROW

Harrow to Participate in Two Investor Conferences in November

· Issued by Harrow, Inc. via GlobeNewswire

Summary by 6ix AI

Harrow, which sells eye-disease treatments in North America, said its management will take part in the Craig-Hallum 17th Annual Alpha Select Conference on Tuesday, November 17, 2026 in New York, NY, and the 2026 Jefferies Global Healthcare Conference on Wednesday, November 18, 2026 in London, UK.

Key details

  • At the Craig-Hallum conference, management will hold one-on-one investor meetings.
  • At the Jefferies conference, management will give a presentation at 8:00 a.m. GMT (3:00 a.m. ET) on November 18, 2026 and hold one-on-one investor meetings.
  • The Jefferies presentation will be webcast live on the Events page of Harrow's website, with a replay available for approximately 90 days afterward.
  • Investors wanting to meet management at either conference should contact their representative at the sponsoring firm.

6ix AI wrote this summary from the release below and checked it against the release.

NASHVILLE, Tenn., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following investor conferences in November:

Craig-Hallum 17th Annual Alpha Select Conference

  • Format: 1x1 investor meetings
  • Date: Tuesday, November 17, 2026
  • Location: New York, NY

2026 Jefferies Global Healthcare Conference

  • Format: Presentation and 1x1 investor meetings
  • Date/Time: Wednesday, November 18, 2026 at 8:00 a.m. GMT (3:00 a.m. ET)
  • Location: London, UK

The Jefferies presentation will be webcast live and can be accessed on the Events page of the Company’s website. A replay of the webcast will be available for approximately 90 days following the presentation. Investors interested in meeting with management during either of these conferences should contact their representative at the sponsoring firm to request a meeting.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Contact:
Mike Biega
Vice President of Investor Relations and Communications
[email protected]
617-913-8890

View original source (GlobeNewswire)Harrow, Inc. on 6ix

Story so far

Earlier from Harrow

All Harrow news releases